Corrigendum

Corrigendum to “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years”

Table 4

Overall complication probabilities for used ADMs.

ADMHADM (Epiflex® / DIZG), PADM (Strattice® / LifeCell), BADM (Tutomesh® / rti surgical)
Breasts (total)52
Median follow-up time (in months)36 (12-54)
Complications (total)9 (17%)

Short-term complicationsSkin necrosis2 (4%)
Seroma1 (2%)
Haematoma0 (0%)
Infection2 (4%)
RBS3 (6%)

Long-term complicationsCapsular contracture3 (6%)
Implant malposition0 (0%)
Implant loss1 (2%)

Short-term (skin necrosis, seroma, haematoma, infection, and Red Breast Syndrome (RBS)) and long-term complications (capsular contracture, implant malposition, and implant loss) for all breasts with usage of ADMs (human ADM (HADM), porcine ADM (PADM), and bovine ADM (BADM)), median follow-up time for all patients, and total complications of all breasts being reconstructed with ADMs; denotes being excluded from overall complications and requiring further medical treatment; denote >Baker-St. II.